Linagliptin Sandoz (Linagliptin)

Linagliptin works by selectively blocking the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of the incretin hormones GLP‑1 and GIP, which increases their circulating levels. Higher incretin concentrations stimulate insulin release in a glucose‑dependent manner and suppress glucagon secretion, leading to reduced hepatic glucose production and lower blood glucose.

The appropriate dose of linagliptin is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. Linagliptin is typically taken once daily, with or without food, but the exact strength and regimen must follow the prescriber’s order and local labeling requirements.

Safety data for linagliptin in pregnancy and lactation are limited. The drug should only be used during pregnancy or while breastfeeding if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss alternative treatments and closely monitor both mother and child if linagliptin is considered.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Linagliptin Sandoz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is a non‑peptidic DPP‑4 inhibitor that does not require dose adjustment in mild to moderate renal impairment, unlike some other agents in the class. Its pharmacokinetic profile provides once‑daily dosing and a low potential for drug‑drug interactions. Efficacy in lowering HbA1c is comparable to other DPP‑4 inhibitors, while safety and tolerability are similar across the class.

Linagliptin Sandoz tablets should be stored at room temperature, typically below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture, light and excessive heat. Do not store in the bathroom or near a kitchen stove, and keep out of reach of children.

Linagliptin Sandoz is taken orally, usually once a day. The tablet can be swallowed whole with water and may be taken with or without food. Patients should follow the dosing instructions provided by their healthcare professional and should not split, crush or chew the tablet unless specifically advised.

The most serious risks include pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and rare skin disorders like bullous pemphigoid or Stevens‑Johnson syndrome. Additionally, when combined with insulin or sulfonylureas, there is an increased risk of severe hypoglycemia. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling or signs of low blood sugar.

Linagliptin is contraindicated in individuals with a known hypersensitivity to linagliptin or any component of the formulation. It should also be avoided in patients who have experienced severe pancreatitis or allergic reactions to other DPP‑4 inhibitors. Caution is advised for patients with significant renal or hepatic impairment, and the drug should be used only under medical supervision in these populations.